# rheumatoid arthritis - grok-4.6

- Benchmark system: E2seq + Agent RAG
- Repeat: 3
- Task type: DISEASE-STATE
- Tissue / sample source: synovial tissue
- Comparison or endpoint: rheumatoid arthritis versus normal control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: xAI / grok-4.6
- Message SHA-256: d868ce3efb219458b8d5ddb7b123eef3f2b718852ba0ede74f2a02e9181db293
- Response HTTP status: 200
- Prompt tokens: 33349
- Completion tokens: 10759
- Reasoning tokens: 7002
- Total tokens: 44108
- API requests reported: 2
- Elapsed seconds: 67.988
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 984.622
- Question handoff seconds: 999.892
- Final benchmark system: E2seq; file rank 1/5; original repeat 3; model vendor: xAI

---
**1. Overall biological interpretation**  
The transcriptomic results from RA synovial tissue versus normal control show coordinated downregulation of 100 genes (log2FC range –2.28 to –5.10, FDR < 10^{-35}), encompassing protein-coding genes involved in polarity and adhesion alongside abundant non-coding RNAs. This pattern integrates multiple genes and their effect directions into a coherent picture of impaired cell polarity, structural matrix support, and RNA regulatory networks in the diseased joint, potentially contributing to synovial inflammation and remodeling.

**2. Core biological programs**  
**Program 1: Hippo signaling pathway**  
Direction: downregulated  
Major supporting genes: SCRIB, ARVCF, APC2  
The most appropriate standardized pathway: Hippo signaling pathway (KEGG)  
The supporting genes collectively indicate this program because SCRIB, ARVCF, and APC2 participate in the core Hippo cascade (including CTNNB1 regulation and polarity complexes); their coordinated repression may suppress contact inhibition and promote proliferative signaling in RA synovium.  
The strength of the evidence is moderate—supported by multiple independent genes in the input dataset plus STRING interactions—but major limitations include the absence of direct Hippo genes in the cohort and lack of external RA-specific replication statistics.  

**Program 2: Ribosome biogenesis in eukaryotes**  
Direction: downregulated  
Major supporting genes: ELOA3BP, ELOA3P, ELOA3  
The most appropriate standardized pathway: KEGG Ribosome biogenesis in eukaryotes  
The supporting genes collectively indicate this program because these elongation factors are essential for ribosomal RNA maturation and protein synthesis; their uniform repression suggests reduced translational capacity and biosynthetic activity in RA synovium.  
The strength of the evidence is moderate—supported by batch-selected KEGG annotations and multiple genes—but major limitations include the indirect nature of the link (few direct ribosomal genes present) and the high proportion of non-coding RNAs in the full cohort.  

**Program 3: Mucin-related extracellular matrix organization**  
Direction: downregulated  
Major supporting genes: MUC12, MUC5B, MUC6  
The most appropriate standardized pathway: GO biological_process “extracellular matrix organization”  
The supporting genes collectively indicate this program through their shared secreted mucin function and STRING co-expression/network links (e.g., MUC1–MUC12/MUC7 edges); coordinated repression may impair synovial lubrication and matrix integrity.  
The strength of the evidence is moderate—supported by direct dataset values plus STRING interactions—but major limitations include the absence of independent RA cohort statistics and possible confounding by mixed synovial cell populations.

**3. Key genes and interaction modules**  
- **SCRIB**: strongly downregulated (log2FC = –3.235, FDR = 1.317e-42); central to Hippo signaling program; direct physical interaction with ARHGEF7 and VANGL2 (STRING confidence 0.997/0.996).  
- **GJC2**: downregulated (log2FC = –3.496, FDR = 5.114e-40); role in cell-communication program; direct physical interaction with GJB2 (STRING confidence 0.792).  
- **ARVCF**: downregulated (log2FC = –3.462, FDR = 1.008e-38); Hippo program; direct physical interaction with CTNNB1 (STRING confidence 0.804).  
- **APC2**: downregulated (log2FC = –3.018, FDR = 4.634e-39); Hippo program; indirect relationship via CTNNB1–ARVCF co-expression.  
- **MUC5B**: downregulated (log2FC = –4.426, FDR = 2.068e-40); mucin-related program; regulatory interaction with MUC12 and MUC6 (STRING).  
- **CDHR5**: downregulated (log2FC = –4.224, FDR = 1.613e-45); adhesion/junction module; pathway co-membership with CDHR5-related cadherins.  
- **FAM47A**: extremely downregulated (log2FC = –5.018, FDR = 1.758e-37); non-coding RNA regulatory module; putative regulatory interaction within lncRNA/miRNA cluster.  
- **MIR3154**: extremely downregulated (log2FC = –5.101, FDR = 5.973e-43); miRNA regulatory module; regulatory interaction within non-coding RNA network.  
- **MUC12**: downregulated (log2FC = –4.270, FDR = 6.049e-43); mucin-related program; co-expression with MUC5B/MUC6.  
- **ELOA3BP**: downregulated (log2FC = –3.533, FDR = 1.424e-35); ribosome biogenesis program; pathway co-membership with ELOA3P/ELOA3.

**4. Validation priorities**  
1. **qPCR validation of SCRIB, ARVCF, GJC2, and ELOA3BP in independent RA synovium cohorts**  
   Why prioritized: largest effect sizes and network support within Hippo and ribosome programs.  
   Evidence provided by current dataset: direct log2FC/FDR values plus STRING edges.  
   External evidence: gtex tissue-specific records for 61 genes and gwas records for all genes; no independent-cohort statistics supplied.  
   Most appropriate next step: single-cell RNA-seq deconvolution followed by targeted qPCR.  
   Current conclusion: supported hypothesis (external statistical validation was not performed).  

2. **Functional knockdown of top miRNA/lncRNA (MIR3154, FAM47A) in RA synovial fibroblasts**  
   Why prioritized: extreme effect sizes and enrichment for non-coding regulatory networks.  
   Evidence provided by current dataset: dataset downregulation and batch non-coding representation.  
   External evidence: insufficient RA-specific functional data; general miRNA roles in inflammation only.  
   Most appropriate next step: in-vitro RA fibroblast models with cytokine stimulation.  
   Current conclusion: exploratory hypothesis (external statistical validation was not performed).  

3. **Single-cell RNA-seq to assess cell-type-specific expression and potential composition bias**  
   Why prioritized: mixed synovial tissue raises confounding risk.  
   Evidence provided by current dataset: average downregulation across 100 genes.  
   External evidence: gtex records for 61 genes; no RA single-cell statistics supplied.  
   Most appropriate next step: compare RA versus control synovium scRNA-seq with cell-type deconvolution.  
   Current conclusion: confounding or composition check (external statistical validation was not performed).  

4. **Pathway re-enrichment in additional public RA transcriptomic cohorts**  
   Why prioritized: current programs rely on batch-selected KEGG/GO terms.  
   Evidence provided by current dataset: dataset statistics plus batch pathway overlap.  
   External evidence: no external FDR/P values supplied; PubMed/Europe PMC records retrieved are unrelated to RA (e.g., cancer or disc degeneration).  
   Most appropriate next step: GSEA on independent RA datasets.  
   Current conclusion: exploratory hypothesis (external statistical validation was not performed).  

5. **Investigation of treatment-exposure or disease-stage stratification effects**  
   Why prioritized: RA heterogeneity and lack of subgroup data.  
   Evidence provided by current dataset: uniform downregulation without stratification.  
   External evidence: no severity-matched controls or medication-status statistics supplied.  
   Most appropriate next step: stratified analysis by DAS28 or medication history.  
   Current conclusion: confounding or composition check (external statistical validation was not performed).

**5. Evidence grounding**  
All statistical values (log2FC, P, FDR) derive directly from the uploaded cohort. Pathway assignments are from the batch-selected KEGG terms (Ribosome biogenesis in eukaryotes, Hippo signaling pathway) and GO annotations. Network relationships are supported by STRING edges (e.g., SCRIB–ARHGEF7 direct physical, GJC2–GJB2 direct physical). Disease-association evidence exists via gwas records for all 100 genes and tissue-specific expression via gtex for 61 genes. Published literature records retrieved (PubMed 483, Europe PMC 776) are unrelated to RA mechanisms (e.g., pancreatic cancer, prostate cancer, SKCM) and therefore provide insufficient evidence for RA-specific claims. No independent-cohort statistics were supplied; pathway, interaction, and tissue records are contextual only and not used to replace or filter the input statistics.

**6. Limitations and alternative explanations**  
- Synovial tissue cellular composition differences between RA patients and controls can alter average expression if immune-cell or fibroblast proportions vary.  
- Disease-stage or treatment-exposure heterogeneity among patients may mask or exaggerate signals.  
- High proportion of uncharacterized LOC genes and non-coding RNAs with sparse prior functional annotation limits mechanistic interpretation.  
- Association-versus-causation ambiguity: downregulation may be a consequence rather than driver of RA.  
- Potential batch or platform effects, although not flagged in the ledger.  
These possibilities could be investigated by single-cell RNA-seq or matched cell-type controls.  

The observed transcriptional repression pattern provides a robust starting point for hypothesis generation but requires independent cohort confirmation and functional validation to establish biological or clinical relevance in rheumatoid arthritis.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=10, external claims checked=0, external mismatches=0, status=passed.

Answer model API: xAI / grok-4.6

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 84/100 selected items (records returned); cbioportal 82/100 selected items (records returned); chembl 16/100 selected items (records returned); civic 1/100 selected items (records returned); clinicaltrials 19/100 selected items (records returned); clinvar 79/100 selected items (records returned); ensembl 40/100 selected items (partially returned; some queries failed); europepmc 776 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 61/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 47/100 selected items (records returned); humanbase 88/100 selected items (partially returned; some queries failed); intact 47/100 selected items (records returned); mygene 93/100 selected items (records returned); omnipath 17/100 selected items (records returned); opentargets 82/100 selected items (records returned); pubmed 483 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 50/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 51/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 8/100 selected items (records returned); string 49/100 selected items (records returned); trrust 7/100 selected items (records returned)
